Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has received a written notification from the Nasdaq Listing Qualifications Department indicating non-compliance with the Nasdaq Capital Market's minimum bid price requirement. The notice, dated March 12, 2026, was triggered after the company's American Depositary Shares traded below $1.00 for 30 consecutive business days.
The notification has no immediate impact on the listing or trading of Scinai's ADSs. The company has been granted a 180-day compliance period through September 8, 2026, during which it may regain compliance if its closing bid price meets or exceeds $1.00 for at least 10 consecutive business days. This grace period provides Scinai with critical time to address market valuation concerns while continuing its operations.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Additionally, Scinai owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization that provides development and manufacturing services to biotechnology and pharmaceutical companies.
The Nasdaq compliance notice reflects broader challenges facing development-stage biotech companies, particularly those in the competitive immunology space. Maintaining minimum share price requirements is essential for continued access to public markets, which provide crucial capital for research-intensive companies like Scinai. The company's ability to regain compliance within the 180-day period will depend on both market conditions and investor confidence in its therapeutic pipeline and CDMO business.
For business and technology leaders, this development underscores the financial pressures facing innovative biotech firms as they balance research investments with market expectations. The situation highlights the importance of sustainable financial strategies for companies developing cutting-edge medical technologies. Scinai's dual focus on therapeutic development and CDMO services represents a strategic approach to revenue diversification common in the biotech sector.
Investors and industry observers can monitor Scinai's progress toward compliance through the company's official communications. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI. The full press release regarding the Nasdaq notice can be viewed at https://ibn.fm/faOR5.
